Omnadren® 250 (in its original formulation), was an oilbased injectable testosterone blend that contained four different testosterone esters: testosterone propionate (30 mg); testosterone phenylpropionate (60 mg); testosterone isocaproate (60 mg); and testosterone caproate (100 mg). Being a four-component testosterone blend, this preparation was most commonly compared to Sustanon® 250. While it did contain testosterone propionate, phenylpropionate, and isocaproate in the same strengths as Sustanon®, the last ester is different. It was a slightly shorter-acting drug, making Omnadren® more analogous to Testoviron® (the caproate ester is one carbon shorter than enanthate) than Sustanon® 250. Please note that there were even older versions of Omnadren® listing isohexanoate and hexanoate as the final two ingredients, which are simply different words for isocaproate and caproate.
Omnadren® 250 was developed in Poland by Polfa during the years of Soviet control. Its formulation (original) is very similar to that of Sustanon® 250, barring the substitution of one of the component esters. This was likely done to avoid patent issues with the international pharmaceutical giant Organon, which exclusively controlled the global supply of Sustanon® 250. In clinical medicine, Omnadren® 250 was used most commonly to treat adult men suffering from low androgen levels, usually noticing symptoms of impotence or hormonal disturbance of spermatogenesis. This drug was also used on occasion to treat adolescents with delayed puberty, and women with advanced breast or endometrial cancer. The manufacture of Omnadren® 250 under the Polfa label was discontinued in 1994. That year, the newly privatized Polfa firm was renamed Jelfa, mainly to distinguish itself from other firms that use a Polfa prefix as part of their names. Jelfa continued to produce Omnadren® 250 for the domestic market, which remained available without interruption in the same familiar 5-pack of ampules (albeit with a new company label and logo) for years after.
Omnadren® 250 contains a mixture of four testosterone compounds, which where modified with the addition of carboxylic acid esters (propionic, propionic phenyl ester, isocaproic, and caproic acids) at the 17-beta hydroxyl group. Esterified forms of testosterone are less polar than free testosterone, and are absorbed more slowly from the area of injection. Once in the bloodstream, the ester is removed to yield free (active) testosterone. Esterified forms of testosterone are designed to prolong the window of therapeutic effect following administration, allowing for a less frequent injection schedule compared to injections of free (unesterified) steroid. Omnadren® 250 is designed to provide a rapid peak in testosterone levels (24-48 hours after injection), and maintain physiological concentrations for approximately 14 days.
Side Effects (Estrogenic):
Testosterone is readily aromatized in the body to estradiol (estrogen). The aromatase (estrogen synthetase) enzyme is responsible for this metabolism of testosterone. Elevated estrogen levels can cause side effects such as increased water retention, body fat gain, and gynecomastia. Testosterone is considered a moderately estrogenic steroid. An anti-estrogen such as clomiphene citrate or tamoxifen citrate may be necessary to prevent estrogenic side effects. One may alternately use an aromatase inhibitor like Arimidex® (anastrozole), which more efficiently controls estrogen by preventing its synthesis. Aromatase inhibitors can be quite expensive in comparison to anti-estrogens, however, and may also have negative effects on blood lipids. Estrogenic side effects will occur in a dose-dependant manner, with higher doses (above normal therapeutic levels) of testosterone more likely to require the concurrent use of an anti-estrogen or aromatase inhibitor. Since water retention and loss of muscle definition are common with higher doses of testosterone, this drug is usually considered a poor choice for dieting or cutting phases of training. Its moderate estrogenicity makes it more ideal for bulking phases, where the added water retention will support raw strength and muscle size, and help foster a stronger anabolic environment.
Side Effects (Androgenic):
Testosterone is the primary male androgen, responsible for maintaining secondary male sexual characteristics. Elevated levels of testosterone are likely to produce androgenic side effects including oily skin, acne, and body/facial hair growth. Men with a genetic predisposition for hair loss (androgenetic alopecia) may notice accelerated male pattern balding. Those concerned about hair loss may find a more comfortable option in nandrolone decanoate, which is a comparably less androgenic steroid. Women are warned of the potential virilizing effects of anabolic/androgenic steroids, especially with a strong androgen such as testosterone. These may include deepening of the voice, menstrual irregularities, changes in skin texture, facial hair growth, and clitoral enlargement. In androgen-responsive target tissues such as the skin, scalp, and prostate, the high relative androgenicity of testosterone is dependant on its reduction to dihydrotestosterone (DHT). The 5-alpha reductase enzyme is responsible for this metabolism of testosterone. The concurrent use of a 5-alpha reductase inhibitor such as finasteride or dutasteride will interfere with site-specific potentiation of testosterone action, lowering the tendency of testosterone drugs to produce androgenic side effects. It is important to remember that anabolic and androgenic effects are both mediated via the cytosolic androgen receptor. Complete separation of testosterone’s anabolic and androgenic properties is not possible, even with total 5-alpha reductase inhibition.
Side Effects (Hepatotoxicity):
Testosterone does not have hepatotoxic effects; liver toxicity is unlikely. One study examined the potential for hepatotoxicity with high doses of testosterone by administering 400 mg of the hormone per day (2, mg per week) to a group of male subjects. The steroid was taken orally so that higher peak concentrations would be reached in hepatic tissues compared to intramuscular injections. The hormone was given daily for 20 days, and produced no significant changes in liver enzyme values including serum albumin, bilirubin, alanine-amino-transferase, and alkaline phosphatases.
• Molecular Weight (of Base): 288.429
• Molecular Weight (esters)
• Propionate: 362.5082
• Phenylpropionate: 438.6058
• Isocaproate: 404.5886
• Formula (of Base): C19 H28 O2
• Formula (esters)
• Propionate:C3 H6 O2
• Phenylpropionate:C9 H10 O2
• Isocaproate:C6 H12 O2
• Caproate:C16 H12 O2
• Melting Point: 154-155C
• Manufacturer: Jelfa
• Effective dose: 250-1,000mgs/week
• Active Life: 10 days
• Detection Time: 3 months
• Anabolic/Androgenic Ratio: 100:100